Anti-CD19 CAR-T cell
US12234275B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 23, 2020 |
| Grant date | Feb 25, 2025 |
| Priority date | — |
| Expiry date | Nov 29, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A chimeric antigen receptor is provided, including an extracellular segment, including a single-chain antibody region binding to an antigen human CD19 and a hinge region, a trans-membrane segment, including a trans-membrane domain of human CD8α linked to the hinge region of the extracellular segment and embedded in cell membrane of T lymphocyte, and an intracellular segment, including an intracellular domain of human CD8α, an intracellular domain of molecule 4-1BB and an intracellular domain of CD3 ζ chain. The single-chain antibody region includes a heavy-chain variable region and a light-chain variable region of the single-chain antibody, the hinge region includes an extracellular domain of human CD8 alpha (CD8α) of 55 amino acid residues and three alanine residues (AAA) located at the N-terminal of the extracellular domain of human CD8α, and the intracellular domain of human CD8α includes seven amino acid residues and linked to the trans-membrane domain of human CD8α.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.